

# Global Cardiovascular Disease Nursing Drugs Market Growth 2023-2029

<https://marketpublishers.com/r/G4E120264F77EN.html>

Date: January 2023

Pages: 105

Price: US\$ 3,660.00 (Single User License)

ID: G4E120264F77EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the “Cardiovascular Disease Nursing Drugs Industry Forecast” looks at past sales and reviews total world Cardiovascular Disease Nursing Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Cardiovascular Disease Nursing Drugs sales for 2023 through 2029. With Cardiovascular Disease Nursing Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Cardiovascular Disease Nursing Drugs industry.

This Insight Report provides a comprehensive analysis of the global Cardiovascular Disease Nursing Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cardiovascular Disease Nursing Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cardiovascular Disease Nursing Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cardiovascular Disease Nursing Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cardiovascular Disease Nursing Drugs.

The global Cardiovascular Disease Nursing Drugs market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cardiovascular Disease Nursing Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cardiovascular Disease Nursing Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cardiovascular Disease Nursing Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cardiovascular Disease Nursing Drugs players cover Crestor, Zetia, Vytorin, Letairis, Tracleer, Bystolic, Opsumit, Ranexa and Azilva, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular Disease Nursing Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Antihypertensive Drugs

Antianginal Drugs

Anticoagulants

Antilipidemic Drugs

Anti-heart Failure Drugs

Antiarrhythmic Drugs

## Segmentation by application

Hospital

Institute of Medicine

Clinic

Others

## This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Crestor

Zetia

Vytorin

Letairis

Tracleer

Bystolic

Opsumit

Ranexa

Azilva

Remodulin

### Key Questions Addressed in this Report

What is the 10-year outlook for the global Cardiovascular Disease Nursing Drugs market?

What factors are driving Cardiovascular Disease Nursing Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Cardiovascular Disease Nursing Drugs market opportunities vary by end market size?

How does Cardiovascular Disease Nursing Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Cardiovascular Disease Nursing Drugs Annual Sales 2018-2029
  - 2.1.2 World Current & Future Analysis for Cardiovascular Disease Nursing Drugs by Geographic Region, 2018, 2022 & 2029
  - 2.1.3 World Current & Future Analysis for Cardiovascular Disease Nursing Drugs by Country/Region, 2018, 2022 & 2029
- 2.2 Cardiovascular Disease Nursing Drugs Segment by Type
  - 2.2.1 Antihypertensive Drugs
  - 2.2.2 Antianginal Drugs
  - 2.2.3 Anticoagulants
  - 2.2.4 Antilipidemic Drugs
  - 2.2.5 Anti-heart Failure Drugs
  - 2.2.6 Antiarrhythmic Drugs
- 2.3 Cardiovascular Disease Nursing Drugs Sales by Type
  - 2.3.1 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2023)
  - 2.3.2 Global Cardiovascular Disease Nursing Drugs Revenue and Market Share by Type (2018-2023)
  - 2.3.3 Global Cardiovascular Disease Nursing Drugs Sale Price by Type (2018-2023)
- 2.4 Cardiovascular Disease Nursing Drugs Segment by Application
  - 2.4.1 Hospital
  - 2.4.2 Institute of Medicine
  - 2.4.3 Clinic
  - 2.4.4 Others

## 2.5 Cardiovascular Disease Nursing Drugs Sales by Application

2.5.1 Global Cardiovascular Disease Nursing Drugs Sale Market Share by Application (2018-2023)

2.5.2 Global Cardiovascular Disease Nursing Drugs Revenue and Market Share by Application (2018-2023)

2.5.3 Global Cardiovascular Disease Nursing Drugs Sale Price by Application (2018-2023)

## **3 GLOBAL CARDIOVASCULAR DISEASE NURSING DRUGS BY COMPANY**

### 3.1 Global Cardiovascular Disease Nursing Drugs Breakdown Data by Company

3.1.1 Global Cardiovascular Disease Nursing Drugs Annual Sales by Company (2018-2023)

3.1.2 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Company (2018-2023)

3.2 Global Cardiovascular Disease Nursing Drugs Annual Revenue by Company (2018-2023)

3.2.1 Global Cardiovascular Disease Nursing Drugs Revenue by Company (2018-2023)

3.2.2 Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Company (2018-2023)

3.3 Global Cardiovascular Disease Nursing Drugs Sale Price by Company

3.4 Key Manufacturers Cardiovascular Disease Nursing Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Cardiovascular Disease Nursing Drugs Product Location Distribution

3.4.2 Players Cardiovascular Disease Nursing Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

## **4 WORLD HISTORIC REVIEW FOR CARDIOVASCULAR DISEASE NURSING DRUGS BY GEOGRAPHIC REGION**

4.1 World Historic Cardiovascular Disease Nursing Drugs Market Size by Geographic Region (2018-2023)

4.1.1 Global Cardiovascular Disease Nursing Drugs Annual Sales by Geographic

## Region (2018-2023)

4.1.2 Global Cardiovascular Disease Nursing Drugs Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Cardiovascular Disease Nursing Drugs Market Size by Country/Region (2018-2023)

4.2.1 Global Cardiovascular Disease Nursing Drugs Annual Sales by Country/Region (2018-2023)

4.2.2 Global Cardiovascular Disease Nursing Drugs Annual Revenue by Country/Region (2018-2023)

4.3 Americas Cardiovascular Disease Nursing Drugs Sales Growth

4.4 APAC Cardiovascular Disease Nursing Drugs Sales Growth

4.5 Europe Cardiovascular Disease Nursing Drugs Sales Growth

4.6 Middle East & Africa Cardiovascular Disease Nursing Drugs Sales Growth

## 5 AMERICAS

5.1 Americas Cardiovascular Disease Nursing Drugs Sales by Country

5.1.1 Americas Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023)

5.1.2 Americas Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023)

5.2 Americas Cardiovascular Disease Nursing Drugs Sales by Type

5.3 Americas Cardiovascular Disease Nursing Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## 6 APAC

6.1 APAC Cardiovascular Disease Nursing Drugs Sales by Region

6.1.1 APAC Cardiovascular Disease Nursing Drugs Sales by Region (2018-2023)

6.1.2 APAC Cardiovascular Disease Nursing Drugs Revenue by Region (2018-2023)

6.2 APAC Cardiovascular Disease Nursing Drugs Sales by Type

6.3 APAC Cardiovascular Disease Nursing Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India



6.9 Australia

6.10 China Taiwan

## **7 EUROPE**

7.1 Europe Cardiovascular Disease Nursing Drugs by Country

7.1.1 Europe Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023)

7.1.2 Europe Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023)

7.2 Europe Cardiovascular Disease Nursing Drugs Sales by Type

7.3 Europe Cardiovascular Disease Nursing Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Cardiovascular Disease Nursing Drugs by Country

8.1.1 Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023)

8.1.2 Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023)

8.2 Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Type

8.3 Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Cardiovascular Disease Nursing Drugs
- 10.3 Manufacturing Process Analysis of Cardiovascular Disease Nursing Drugs
- 10.4 Industry Chain Structure of Cardiovascular Disease Nursing Drugs

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

- 11.1 Sales Channel
  - 11.1.1 Direct Channels
  - 11.1.2 Indirect Channels
- 11.2 Cardiovascular Disease Nursing Drugs Distributors
- 11.3 Cardiovascular Disease Nursing Drugs Customer

## **12 WORLD FORECAST REVIEW FOR CARDIOVASCULAR DISEASE NURSING DRUGS BY GEOGRAPHIC REGION**

- 12.1 Global Cardiovascular Disease Nursing Drugs Market Size Forecast by Region
  - 12.1.1 Global Cardiovascular Disease Nursing Drugs Forecast by Region (2024-2029)
  - 12.1.2 Global Cardiovascular Disease Nursing Drugs Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Cardiovascular Disease Nursing Drugs Forecast by Type
- 12.7 Global Cardiovascular Disease Nursing Drugs Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

- 13.1 Crestor
  - 13.1.1 Crestor Company Information
  - 13.1.2 Crestor Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.1.3 Crestor Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.1.4 Crestor Main Business Overview
  - 13.1.5 Crestor Latest Developments
- 13.2 Zetia
  - 13.2.1 Zetia Company Information

- 13.2.2 Zetia Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
- 13.2.3 Zetia Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Zetia Main Business Overview
- 13.2.5 Zetia Latest Developments
- 13.3 Vytorin
  - 13.3.1 Vytorin Company Information
  - 13.3.2 Vytorin Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.3.3 Vytorin Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.3.4 Vytorin Main Business Overview
  - 13.3.5 Vytorin Latest Developments
- 13.4 Letairis
  - 13.4.1 Letairis Company Information
  - 13.4.2 Letairis Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.4.3 Letairis Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.4.4 Letairis Main Business Overview
  - 13.4.5 Letairis Latest Developments
- 13.5 Tracleer
  - 13.5.1 Tracleer Company Information
  - 13.5.2 Tracleer Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.5.3 Tracleer Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.5.4 Tracleer Main Business Overview
  - 13.5.5 Tracleer Latest Developments
- 13.6 Bystolic
  - 13.6.1 Bystolic Company Information
  - 13.6.2 Bystolic Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.6.3 Bystolic Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.6.4 Bystolic Main Business Overview
  - 13.6.5 Bystolic Latest Developments
- 13.7 Opsumit

- 13.7.1 Opsumit Company Information
- 13.7.2 Opsumit Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
- 13.7.3 Opsumit Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.7.4 Opsumit Main Business Overview
- 13.7.5 Opsumit Latest Developments
- 13.8 Ranexa
  - 13.8.1 Ranexa Company Information
  - 13.8.2 Ranexa Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.8.3 Ranexa Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.8.4 Ranexa Main Business Overview
  - 13.8.5 Ranexa Latest Developments
- 13.9 Azilva
  - 13.9.1 Azilva Company Information
  - 13.9.2 Azilva Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.9.3 Azilva Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.9.4 Azilva Main Business Overview
  - 13.9.5 Azilva Latest Developments
- 13.10 Remodulin
  - 13.10.1 Remodulin Company Information
  - 13.10.2 Remodulin Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
  - 13.10.3 Remodulin Cardiovascular Disease Nursing Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.10.4 Remodulin Main Business Overview
  - 13.10.5 Remodulin Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

- Table 1. Cardiovascular Disease Nursing Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Cardiovascular Disease Nursing Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Antihypertensive Drugs
- Table 4. Major Players of Antianginal Drugs
- Table 5. Major Players of Anticoagulants
- Table 6. Major Players of Antilipidemic Drugs
- Table 7. Major Players of Anti-heart Failure Drugs
- Table 8. Major Players of Antiarrhythmic Drugs
- Table 9. Global Cardiovascular Disease Nursing Drugs Sales by Type (2018-2023) & (K Units)
- Table 10. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2023)
- Table 11. Global Cardiovascular Disease Nursing Drugs Revenue by Type (2018-2023) & (\$ million)
- Table 12. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Type (2018-2023)
- Table 13. Global Cardiovascular Disease Nursing Drugs Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 14. Global Cardiovascular Disease Nursing Drugs Sales by Application (2018-2023) & (K Units)
- Table 15. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2023)
- Table 16. Global Cardiovascular Disease Nursing Drugs Revenue by Application (2018-2023)
- Table 17. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Application (2018-2023)
- Table 18. Global Cardiovascular Disease Nursing Drugs Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 19. Global Cardiovascular Disease Nursing Drugs Sales by Company (2018-2023) & (K Units)
- Table 20. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Company (2018-2023)
- Table 21. Global Cardiovascular Disease Nursing Drugs Revenue by Company

(2018-2023) (\$ Millions)

Table 22. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Company (2018-2023)

Table 23. Global Cardiovascular Disease Nursing Drugs Sale Price by Company (2018-2023) & (US\$/Unit)

Table 24. Key Manufacturers Cardiovascular Disease Nursing Drugs Producing Area Distribution and Sales Area

Table 25. Players Cardiovascular Disease Nursing Drugs Products Offered

Table 26. Cardiovascular Disease Nursing Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Cardiovascular Disease Nursing Drugs Sales by Geographic Region (2018-2023) & (K Units)

Table 30. Global Cardiovascular Disease Nursing Drugs Sales Market Share Geographic Region (2018-2023)

Table 31. Global Cardiovascular Disease Nursing Drugs Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 32. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Geographic Region (2018-2023)

Table 33. Global Cardiovascular Disease Nursing Drugs Sales by Country/Region (2018-2023) & (K Units)

Table 34. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Country/Region (2018-2023)

Table 35. Global Cardiovascular Disease Nursing Drugs Revenue by Country/Region (2018-2023) & (\$ millions)

Table 36. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Country/Region (2018-2023)

Table 37. Americas Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023) & (K Units)

Table 38. Americas Cardiovascular Disease Nursing Drugs Sales Market Share by Country (2018-2023)

Table 39. Americas Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 40. Americas Cardiovascular Disease Nursing Drugs Revenue Market Share by Country (2018-2023)

Table 41. Americas Cardiovascular Disease Nursing Drugs Sales by Type (2018-2023) & (K Units)

Table 42. Americas Cardiovascular Disease Nursing Drugs Sales by Application

(2018-2023) & (K Units)

Table 43. APAC Cardiovascular Disease Nursing Drugs Sales by Region (2018-2023) & (K Units)

Table 44. APAC Cardiovascular Disease Nursing Drugs Sales Market Share by Region (2018-2023)

Table 45. APAC Cardiovascular Disease Nursing Drugs Revenue by Region (2018-2023) & (\$ Millions)

Table 46. APAC Cardiovascular Disease Nursing Drugs Revenue Market Share by Region (2018-2023)

Table 47. APAC Cardiovascular Disease Nursing Drugs Sales by Type (2018-2023) & (K Units)

Table 48. APAC Cardiovascular Disease Nursing Drugs Sales by Application (2018-2023) & (K Units)

Table 49. Europe Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023) & (K Units)

Table 50. Europe Cardiovascular Disease Nursing Drugs Sales Market Share by Country (2018-2023)

Table 51. Europe Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 52. Europe Cardiovascular Disease Nursing Drugs Revenue Market Share by Country (2018-2023)

Table 53. Europe Cardiovascular Disease Nursing Drugs Sales by Type (2018-2023) & (K Units)

Table 54. Europe Cardiovascular Disease Nursing Drugs Sales by Application (2018-2023) & (K Units)

Table 55. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023) & (K Units)

Table 56. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales Market Share by Country (2018-2023)

Table 57. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 58. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue Market Share by Country (2018-2023)

Table 59. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Type (2018-2023) & (K Units)

Table 60. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Application (2018-2023) & (K Units)

Table 61. Key Market Drivers & Growth Opportunities of Cardiovascular Disease Nursing Drugs

Table 62. Key Market Challenges & Risks of Cardiovascular Disease Nursing Drugs

Table 63. Key Industry Trends of Cardiovascular Disease Nursing Drugs

Table 64. Cardiovascular Disease Nursing Drugs Raw Material

Table 65. Key Suppliers of Raw Materials

Table 66. Cardiovascular Disease Nursing Drugs Distributors List

Table 67. Cardiovascular Disease Nursing Drugs Customer List

Table 68. Global Cardiovascular Disease Nursing Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 69. Global Cardiovascular Disease Nursing Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Americas Cardiovascular Disease Nursing Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 71. Americas Cardiovascular Disease Nursing Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. APAC Cardiovascular Disease Nursing Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 73. APAC Cardiovascular Disease Nursing Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 74. Europe Cardiovascular Disease Nursing Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 75. Europe Cardiovascular Disease Nursing Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 76. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 77. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 78. Global Cardiovascular Disease Nursing Drugs Sales Forecast by Type (2024-2029) & (K Units)

Table 79. Global Cardiovascular Disease Nursing Drugs Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 80. Global Cardiovascular Disease Nursing Drugs Sales Forecast by Application (2024-2029) & (K Units)

Table 81. Global Cardiovascular Disease Nursing Drugs Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 82. Crestor Basic Information, Cardiovascular Disease Nursing Drugs Manufacturing Base, Sales Area and Its Competitors

Table 83. Crestor Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications

Table 84. Crestor Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$



Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 85. Crestor Main Business

Table 86. Crestor Latest Developments

Table 87. Zetia Basic Information, Cardiovascular Disease Nursing Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 88. Zetia Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications

Table 89. Zetia Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 90. Zetia Main Business

Table 91. Zetia Latest Developments

Table 92. Vytorin Basic Information, Cardiovascular Disease Nursing Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 93. Vytorin Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications

Table 94. Vytorin Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 95. Vytorin Main Business

Table 96. Vytorin Latest Developments

Table 97. Letairis Basic Information, Cardiovascular Disease Nursing Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 98. Letairis Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications

Table 99. Letairis Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 100. Letairis Main Business

Table 101. Letairis Latest Developments

Table 102. Tracleer Basic Information, Cardiovascular Disease Nursing Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 103. Tracleer Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications

Table 104. Tracleer Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 105. Tracleer Main Business

Table 106. Tracleer Latest Developments

Table 107. Bystolic Basic Information, Cardiovascular Disease Nursing Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 108. Bystolic Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications

- Table 109. Bystolic Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 110. Bystolic Main Business
- Table 111. Bystolic Latest Developments
- Table 112. Opsumit Basic Information, Cardiovascular Disease Nursing Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 113. Opsumit Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
- Table 114. Opsumit Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 115. Opsumit Main Business
- Table 116. Opsumit Latest Developments
- Table 117. Ranexa Basic Information, Cardiovascular Disease Nursing Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 118. Ranexa Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
- Table 119. Ranexa Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 120. Ranexa Main Business
- Table 121. Ranexa Latest Developments
- Table 122. Azilva Basic Information, Cardiovascular Disease Nursing Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 123. Azilva Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
- Table 124. Azilva Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 125. Azilva Main Business
- Table 126. Azilva Latest Developments
- Table 127. Remodulin Basic Information, Cardiovascular Disease Nursing Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 128. Remodulin Cardiovascular Disease Nursing Drugs Product Portfolios and Specifications
- Table 129. Remodulin Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 130. Remodulin Main Business
- Table 131. Remodulin Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Picture of Cardiovascular Disease Nursing Drugs

Figure 2. Cardiovascular Disease Nursing Drugs Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Cardiovascular Disease Nursing Drugs Sales Growth Rate 2018-2029 (K Units)

Figure 7. Global Cardiovascular Disease Nursing Drugs Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. Cardiovascular Disease Nursing Drugs Sales by Region (2018, 2022 & 2029) & (\$ Millions)

Figure 9. Product Picture of Antihypertensive Drugs

Figure 10. Product Picture of Antianginal Drugs

Figure 11. Product Picture of Anticoagulants

Figure 12. Product Picture of Antilipidemic Drugs

Figure 13. Product Picture of Anti-heart Failure Drugs

Figure 14. Product Picture of Antiarrhythmic Drugs

Figure 15. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Type in 2022

Figure 16. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Type (2018-2023)

Figure 17. Cardiovascular Disease Nursing Drugs Consumed in Hospital

Figure 18. Global Cardiovascular Disease Nursing Drugs Market: Hospital (2018-2023) & (K Units)

Figure 19. Cardiovascular Disease Nursing Drugs Consumed in Institute of Medicine

Figure 20. Global Cardiovascular Disease Nursing Drugs Market: Institute of Medicine (2018-2023) & (K Units)

Figure 21. Cardiovascular Disease Nursing Drugs Consumed in Clinic

Figure 22. Global Cardiovascular Disease Nursing Drugs Market: Clinic (2018-2023) & (K Units)

Figure 23. Cardiovascular Disease Nursing Drugs Consumed in Others

Figure 24. Global Cardiovascular Disease Nursing Drugs Market: Others (2018-2023) & (K Units)

Figure 25. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2022)

Figure 26. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Application in 2022

Figure 27. Cardiovascular Disease Nursing Drugs Sales Market by Company in 2022 (K Units)

Figure 28. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Company in 2022

Figure 29. Cardiovascular Disease Nursing Drugs Revenue Market by Company in 2022 (\$ Million)

Figure 30. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Company in 2022

Figure 31. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Geographic Region (2018-2023)

Figure 32. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Geographic Region in 2022

Figure 33. Americas Cardiovascular Disease Nursing Drugs Sales 2018-2023 (K Units)

Figure 34. Americas Cardiovascular Disease Nursing Drugs Revenue 2018-2023 (\$ Millions)

Figure 35. APAC Cardiovascular Disease Nursing Drugs Sales 2018-2023 (K Units)

Figure 36. APAC Cardiovascular Disease Nursing Drugs Revenue 2018-2023 (\$ Millions)

Figure 37. Europe Cardiovascular Disease Nursing Drugs Sales 2018-2023 (K Units)

Figure 38. Europe Cardiovascular Disease Nursing Drugs Revenue 2018-2023 (\$ Millions)

Figure 39. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales 2018-2023 (K Units)

Figure 40. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue 2018-2023 (\$ Millions)

Figure 41. Americas Cardiovascular Disease Nursing Drugs Sales Market Share by Country in 2022

Figure 42. Americas Cardiovascular Disease Nursing Drugs Revenue Market Share by Country in 2022

Figure 43. Americas Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2023)

Figure 44. Americas Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2023)

Figure 45. United States Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 46. Canada Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

- Figure 47. Mexico Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 48. Brazil Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 49. APAC Cardiovascular Disease Nursing Drugs Sales Market Share by Region in 2022
- Figure 50. APAC Cardiovascular Disease Nursing Drugs Revenue Market Share by Regions in 2022
- Figure 51. APAC Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2023)
- Figure 52. APAC Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2023)
- Figure 53. China Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 54. Japan Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 55. South Korea Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 56. Southeast Asia Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 57. India Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 58. Australia Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 59. China Taiwan Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 60. Europe Cardiovascular Disease Nursing Drugs Sales Market Share by Country in 2022
- Figure 61. Europe Cardiovascular Disease Nursing Drugs Revenue Market Share by Country in 2022
- Figure 62. Europe Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2023)
- Figure 63. Europe Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2023)
- Figure 64. Germany Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 65. France Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)
- Figure 66. UK Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$

Millions)

Figure 67. Italy Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 68. Russia Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales Market Share by Country in 2022

Figure 70. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue Market Share by Country in 2022

Figure 71. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2023)

Figure 72. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2023)

Figure 73. Egypt Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 74. South Africa Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 75. Israel Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 76. Turkey Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 77. GCC Country Cardiovascular Disease Nursing Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 78. Manufacturing Cost Structure Analysis of Cardiovascular Disease Nursing Drugs in 2022

Figure 79. Manufacturing Process Analysis of Cardiovascular Disease Nursing Drugs

Figure 80. Industry Chain Structure of Cardiovascular Disease Nursing Drugs

Figure 81. Channels of Distribution

Figure 82. Global Cardiovascular Disease Nursing Drugs Sales Market Forecast by Region (2024-2029)

Figure 83. Global Cardiovascular Disease Nursing Drugs Revenue Market Share Forecast by Region (2024-2029)

Figure 84. Global Cardiovascular Disease Nursing Drugs Sales Market Share Forecast by Type (2024-2029)

Figure 85. Global Cardiovascular Disease Nursing Drugs Revenue Market Share Forecast by Type (2024-2029)

Figure 86. Global Cardiovascular Disease Nursing Drugs Sales Market Share Forecast by Application (2024-2029)

Figure 87. Global Cardiovascular Disease Nursing Drugs Revenue Market Share

## Forecast by Application (2024-2029)

## I would like to order

Product name: Global Cardiovascular Disease Nursing Drugs Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G4E120264F77EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4E120264F77EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970